Evidence map›Paper›PMID 42479712›Full record

ReviewJournal of medicinal chemistry2026

Bidentate Metal-Binding Motifs in US FDA Approved Small Molecule Drugs.

Jon T Njardarson, Elisa Tomat

Abstract readReview
In one paragraph

Review in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jon T NjardarsonDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona85721, United States.ORCID 0000-0003-2268-1479
Elisa TomatDepartment of Chemistry and Biochemistry, University of Arizona, Tucson, Arizona85721, United States.ORCID 0000-0002-7075-9501

Funding

Coordination chemistry approaches to target cellular metal dysregulationR35GM153364 · NIGMS · UNIVERSITY OF ARIZONA · PI TOMAT, ELISA · 2024 to 2025
$723k
Division of Chemistry 2449261NIGMS NIH HHS GM153364NIGMS NIH HHS R35 GM153364
6 · The paper itself

Abstract

The coordination of metal cations is integral to the mechanism of action of metal-binding pharmaceuticals such as scavengers for chelation therapy and metalloprotein inhibitors. Furthermore, clinically relevant interactions with endogenous metals were initially unrecognized for some drug classes and are still debated in some cases. In this Perspective, we survey the small molecules approved as drugs by the United States Food and Drug Administration (US FDA) looking for structural motifs wherein metal ions could potentially coordinate in a bidentate fashion. We focus on the formation of five- or six-membered chelate rings upon coordination with nitrogen, oxygen and sulfur donors. In addition to well-known metal-binding motifs such as hydroxamic acids, catechols and salicylic acids, our review highlights numerous drugs containing 1,3-dicarbonyl motifs and related oxygen donors. Nitrogen heterocycles are also featured prominently in this survey of bidentate motifs and a clear growth category in recent years.

Indexed as

Chelating AgentsDrug ApprovalMetalsSmall Molecule LibrariesHumansUnited StatesUnited States Food and Drug AdministrationChelating AgentsMetalsSmall Molecule Libraries

Identifiers

PMID42479712
PMCPMC13492300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.